Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Do Not Get Us Started on Acthar

Megan Elizabeth Bowles Clowse, MD, MPH & David Leverenz, MD  |  Issue: December 2018  |  December 17, 2018


Megan Elizabeth Bowles Clowse, MD, MPH, is an associate professor of medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine. She is a clinical associate director of Duke Forge, where health data is put into action. Her clinical research focuses on the management of rheumatologic diseases in pregnancy. She is the director of the Vasculitis-Pregnancy Registry. Additionally, she has collected prospective pregnancies in women with rheumatic disease in the Duke Autoimmunity in Pregnancy Registry, which includes clinical data, pregnancy outcomes and a large sample repository. She received her MD from Vanderbilt University and her MPH at the University of California, Los Angeles.

David Leverenz, MD, is pursuing a fellow­ship in rheumatology and immunology at Duke University School of Medicine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Disclosures

Dr. Clowse has received funding from the following sources:

  • Consulting: UCB, Regeneron, AstraZeneca, BMS
  • Investigator-initiated grants: Janssen, Pfizer
  • Independent Medical Education grant: GlaxoSmithKline

Dr. Leverenz has nothing of relevance to disclose.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Collip JB, Anderson EM, Thomson DL. The adrenotropic hormone of the anterior pituitary lobe. Lancet. 1933 Aug 12;222(5737):347–348.
  2. Glyn JH. The discovery of cortisone: A personal memory. BMJ. 1998 Sep 19;317(7161):822.
  3. Pollack A. Questcor finds profits, at $28,000 a vial. The New York Times. 2012 Dec 29.
  4. Hartung DM, Johnston K, Cohen DM, et al. Industry payments to physician specialists who prescribe repository corticotropin. JAMA Network Open. 2018 Jun 29;1(2):e180482.

Editor’s note: Reprinted from Duke Forge by permission.

Page: 1 2 3 | Single Page
Share: 

Filed under:OpinionSpeak Out Rheum Tagged with:Actharadrenocorticotropic hormoneCorticosteroidsDrug UpdatesOpinionprednisone

Related Articles

    Rheumatology with Rhythm

    February 1, 2008

    The circadian rhythm offers insight into treating rheumatic diseases

    Chronotherapy with Glucorticoids in Rheumatoid Arthritis

    January 17, 2011

    Time is of the essence in balancing risks and benefits

    Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

    April 1, 2013

     Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

    How Energy Shifts Lead to Systemic Illness

    July 12, 2011

    The impact of adaptive energy programs on the manifestations of chronic inflammatory disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences